• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Incidence and mortality of thyroid cancer in China, 20082012.2008 - 2012年中国甲状腺癌的发病率和死亡率
Chin J Cancer Res. 2019 Feb;31(1):144-151. doi: 10.21147/j.issn.1000-9604.2019.01.09.
2
Incidence and mortality of lung cancer in China, 20082012.2008 - 2012年中国肺癌的发病率和死亡率
Chin J Cancer Res. 2018 Dec;30(6):580-587. doi: 10.21147/j.issn.1000-9604.2018.06.02.
3
Incidence and mortality of laryngeal cancer in China, 2008-2012.2008 - 2012年中国喉癌的发病率和死亡率
Chin J Cancer Res. 2018 Jun;30(3):299-306. doi: 10.21147/j.issn.1000-9604.2018.03.02.
4
Incidence and mortality of esophagus cancer in China, 20082012.2008 - 2012年中国食管癌的发病率和死亡率
Chin J Cancer Res. 2019 Jun;31(3):426-434. doi: 10.21147/j.issn.1000-9604.2019.03.04.
5
National cancer incidence and mortality in China, 2012.2012年中国国家癌症发病率与死亡率
Chin J Cancer Res. 2016 Feb;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08.
6
[Incidence and mortality of endometrial cancer in China, data from China Cancer Registry Annual Report, 2004-2017].[中国子宫内膜癌的发病率和死亡率,数据来自《中国癌症登记年报》,2004 - 2017年]
Zhonghua Yi Xue Za Zhi. 2024 Mar 12;104(10):721-728. doi: 10.3760/cma.j.cn112137-20231017-00784.
7
Report of incidence and mortality in China cancer registries, 2009.中国癌症登记地区 2009 年肿瘤登记发病与死亡报告
Chin J Cancer Res. 2013 Feb;25(1):10-21. doi: 10.3978/j.issn.1000-9604.2012.12.04.
8
Incidence and mortality of cervical cancer in China in 2015.2015年中国宫颈癌的发病率和死亡率。
J Natl Cancer Cent. 2022 Feb 3;2(2):70-77. doi: 10.1016/j.jncc.2022.01.002. eCollection 2022 Jun.
9
[Changing trend of incidence and mortality of esophageal cancer during 2010-2016 in Henan Province, China].[2010 - 2016年中国河南省食管癌发病率与死亡率的变化趋势]
Zhonghua Zhong Liu Za Zhi. 2022 Jan 23;44(1):86-92. doi: 10.3760/cma.j.cn112152-20200605-00526.
10
Annual report on status of cancer in China, 2010.《中国癌症报告 2010》年度报告
Chin J Cancer Res. 2014 Feb;26(1):48-58. doi: 10.3978/j.issn.1000-9604.2014.01.08.

引用本文的文献

1
Gut microbiome versus thyroid cancer: Association and clinical implications (Review).肠道微生物群与甲状腺癌:关联及临床意义(综述)
Oncol Lett. 2025 May 27;30(1):368. doi: 10.3892/ol.2025.15114. eCollection 2025 Jul.
2
Implications of five endoscopic and conventional open surgery on lateral neck dissection outcomes in patients with papillary thyroid carcinoma: a network meta-analysis and systematic review.五种内镜手术和传统开放手术对乳头状甲状腺癌患者侧颈淋巴结清扫结果的影响:一项网状Meta分析和系统评价
Surg Endosc. 2025 Feb 6. doi: 10.1007/s00464-025-11568-w.
3
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.甲状腺癌中的 BRAF V600E 突变:一项针对汉族人群的大规模研究。
World J Surg Oncol. 2024 Sep 28;22(1):259. doi: 10.1186/s12957-024-03539-7.
4
A new strategy of using low-dose caffeic acid carbon nanodots for high resistance to poorly differentiated human papillary thyroid cancer.使用低剂量咖啡酸碳纳米点的新策略可提高对低分化人甲状腺乳头状癌的耐药性。
J Nanobiotechnology. 2024 Sep 18;22(1):571. doi: 10.1186/s12951-024-02792-y.
5
Thyroid cancer trends in China and its comparative analysis with G20 countries: Projections for 2020-2040.中国甲状腺癌趋势及其与 G20 国家的对比分析:2020-2040 年预测。
J Glob Health. 2024 Jun 14;14:04131. doi: 10.7189/jogh.14.04131.
6
Role of sodium/iodide symporter overexpression in inhibiting thyroid cancer cell invasion and stem cell maintenance by inhibiting the β-catenin/LEF-1 pathway.钠/碘同向转运体过表达通过抑制β-连环蛋白/淋巴样增强因子1信号通路在抑制甲状腺癌细胞侵袭和维持干细胞特性中的作用
Heliyon. 2024 Mar 14;10(6):e27840. doi: 10.1016/j.heliyon.2024.e27840. eCollection 2024 Mar 30.
7
A modified, single-incision, gasless, endoscopic thyroidectomy and bilateral central neck dissection via axillary approach technique for bilateral papillary thyroid microcarcinoma: A preliminary report.改良单切口、无气、经腋窝入路内镜甲状腺切除术及双侧中央区颈淋巴结清扫术治疗双侧甲状腺微小乳头状癌:初步报告
Heliyon. 2024 Jan 23;10(3):e24802. doi: 10.1016/j.heliyon.2024.e24802. eCollection 2024 Feb 15.
8
GPX4 inhibits apoptosis of thyroid cancer cells through regulating the FKBP8/Bcl-2 axis.GPX4 通过调控 FKBP8/Bcl-2 轴抑制甲状腺癌细胞凋亡。
Cancer Biomark. 2024;39(4):349-360. doi: 10.3233/CBM-230220.
9
LRG1 predicts the prognosis and is associated with immune infiltration in thyroid cancer: a bioinformatics study.LRG1预测甲状腺癌的预后并与免疫浸润相关:一项生物信息学研究
Endocr Connect. 2023 Dec 14;13(1). doi: 10.1530/EC-23-0418. Print 2024 Jan 1.
10
Exploring the oral-gut microbiota during thyroid cancer: Factors affecting the thyroid functions and cancer development.探索甲状腺癌期间的口腔-肠道微生物群:影响甲状腺功能和癌症发展的因素。
Food Sci Nutr. 2023 Jul 8;11(10):5657-5674. doi: 10.1002/fsn3.3538. eCollection 2023 Oct.

本文引用的文献

1
Incidence and mortality of lung cancer in China, 20082012.2008 - 2012年中国肺癌的发病率和死亡率
Chin J Cancer Res. 2018 Dec;30(6):580-587. doi: 10.21147/j.issn.1000-9604.2018.06.02.
2
Cancer incidence in Beijing, 2014.2014年北京的癌症发病率
Chin J Cancer Res. 2018 Feb;30(1):13-20. doi: 10.21147/j.issn.1000-9604.2018.01.02.
3
Cancer incidence and mortality in China, 2014.2014年中国的癌症发病率和死亡率
Chin J Cancer Res. 2018 Feb;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01.
4
Psychosocial distress in patients with thyroid cancer.甲状腺癌患者的心理社会困扰
Otolaryngol Head Neck Surg. 2015 Apr;152(4):644-9. doi: 10.1177/0194599814565761. Epub 2015 Jan 8.
5
The role of surgery in the current management of differentiated thyroid cancer.手术在分化型甲状腺癌当前治疗中的作用。
Endocrine. 2014 Nov;47(2):380-8. doi: 10.1007/s12020-014-0251-9. Epub 2014 Apr 10.
6
Head and neck cancer: global burden and regional trends in India.头颈癌:印度的全球负担及区域趋势
Asian Pac J Cancer Prev. 2014;15(2):537-50. doi: 10.7314/apjcp.2014.15.2.537.
7
Current thyroid cancer trends in the United States.美国当前的甲状腺癌趋势。
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22. doi: 10.1001/jamaoto.2014.1.
8
The rising trend of papillary carcinoma in thyroidectomies: 14-years of experience in a referral center of Turkey.甲状腺切除术中乳头状癌的上升趋势:土耳其一家转诊中心的14年经验
World J Surg Oncol. 2014 Feb 10;12:34. doi: 10.1186/1477-7819-12-34.
9
Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study.儿童时期的身高和体重指数与成年后患甲状腺癌的风险相关,这是一项大型队列研究的结果。
Cancer Res. 2014 Jan 1;74(1):235-42. doi: 10.1158/0008-5472.CAN-13-2228. Epub 2013 Nov 18.
10
Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea.基于韩国人口癌症登记处的数据,甲状腺癌是女性中最常见的癌症。
Jpn J Clin Oncol. 2013 Oct;43(10):1039-46. doi: 10.1093/jjco/hyt102. Epub 2013 Jul 25.

2008 - 2012年中国甲状腺癌的发病率和死亡率

Incidence and mortality of thyroid cancer in China, 20082012.

作者信息

Du Lingbin, Li Runhua, Ge Minghua, Wang Youqing, Li Huizhang, Chen Wanqing, He Jie

机构信息

Zhejiang Cancer Center, Zhejiang Cancer Hospital, Hangzhou 310022, China.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100021, China.

出版信息

Chin J Cancer Res. 2019 Feb;31(1):144-151. doi: 10.21147/j.issn.1000-9604.2019.01.09.

DOI:10.21147/j.issn.1000-9604.2019.01.09
PMID:30996572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6433579/
Abstract

OBJECTIVE

To analyze the incidence and mortality rates of thyroid cancer (TC) in China from 2008 to 2012.

METHODS

Incident and death cases of TC were retrieved from the National Central Cancer Registry (NCCR) database collecting from 135 cancer registries in China during 2008-2012. The crude incidence and mortality rates of TC were calculated by area (urban/rural), region (eastern, middle, western), gender and age group (0, 1-4, 5-9, …, 85+). China census in 2000 and world Segi's population were applied for age-standardized rates. Joinpoint (Version 4.6.0.0) model was used for time-trend analysis.

RESULTS

The crude incidence rate of TC was 7.56/100,000 which ranked the seventh in overall cancers. The age-standardized incidence rates by China population (ASIRC) and by World population (ASIRW) were 6.25/100,000 and 5.52/100,000, respectively. The crude mortality of TC in China was 0.52/100,000. The age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 0.34/100,000 and 0.32/100,000, respectively. Incidence and mortality rates of TC were higher in females than in males and higher in urban areas than in rural areas. Eastern areas had the highest incidence followed by middle and western areas. TC incidence increased dramatically after age of 15 years, then peaked at 14.08/100,000 in the group of 50-54 years and finally decreased sharply after 55 years old. TC mortality increased with age in population, reaching the peak of 5.09/100,000 in sub-population aged 85 years or older. TC incidence increased by 4.73 times from 2.40/100,000 in 2003 to 13.75/100,000 in 2012 with an average annual increase of 20%, while TC mortality only increased slightly around 0.32/100,000 from 0.26/100,000 to 0.36/100,000.

CONCLUSIONS

Appropriate targeted prevention, early detection and treatment programs can be carried out to curb the rapid growth trend of TC and control the disease burden.

摘要

目的

分析2008年至2012年中国甲状腺癌(TC)的发病率和死亡率。

方法

从国家癌症中心登记处(NCCR)数据库中检索2008 - 2012年期间中国135个癌症登记处收集的TC发病和死亡病例。按地区(城市/农村)、区域(东部、中部、西部)、性别和年龄组(0、1 - 4、5 - 9、…、85岁及以上)计算TC的粗发病率和死亡率。采用2000年中国人口普查数据和世界Segi人口数据计算年龄标准化率。使用Joinpoint(版本4.6.0.0)模型进行时间趋势分析。

结果

TC的粗发病率为7.56/10万,在所有癌症中排名第七。按中国人口计算的年龄标准化发病率(ASIRC)和按世界人口计算的年龄标准化发病率(ASIRW)分别为6.25/10万和5.52/10万。中国TC的粗死亡率为0.52/10万。按中国标准人口计算的年龄标准化死亡率(ASMRC)和按世界标准人口计算的年龄标准化死亡率(ASMRW)分别为0.34/10万和0.32/10万。TC的发病率和死亡率女性高于男性,城市地区高于农村地区。东部地区发病率最高,其次是中部和西部地区。TC发病率在15岁后急剧上升,然后在50 - 54岁年龄组达到峰值14.08/10万,55岁后急剧下降。TC死亡率随年龄增长而上升,在85岁及以上人群中达到峰值5.09/10万。TC发病率从2003年的2.40/10万增加到2012年的13.75/10万,增长了4.73倍,年均增长20%,而TC死亡率仅从0.26/10万略有增加到0.36/10万左右,约为0.32/10万。

结论

可开展适当的针对性预防、早期检测和治疗项目,以遏制TC的快速增长趋势并控制疾病负担。